

# Mining data to develop planning and treatment quality metrics

SEAAPM Annual Meeting  
Raleigh, NC  
April 23, 2015

Charles Mayo, Ph.D.  
Mayo Clinic, Rochester, MN

## Collaborators

Robert Foote, MD  
Michael Haddock, MD  
Scott Stafford, MD  
Robert Miller, MD  
Yolanda Garces, MD  
Nadia Laack, MD  
Ivy Petersen, MD  
Elizabeth Yan, MD  
Thomas Pisansky, MD  
Kenneth Oliver, MD  
Richard Choo, MD  
Sameer Keole, MD  
Michele Halyard, MD  
Robert Mutter, MD  
Brian Davis, MD, PhD  
Stephanie Childs, MD  
Daniel Ma, MD  
Jan Sarkaria, MD  
James Martenson, MD  
Christopher Hallemeier, MD  
Michele Neben Wittich, MD


Lauren Baker, PMP  
Mark Parry  
Mike Grinnell  
Keith Krupp  
Monty Manley  
  
Chris Brent  
Geri Pumper  
  
Steve Connors

Kristi Klein, RN  
Nancy Heinzelman  
  
Mirek Fatyga, Ph.D.  
Jack Cusma, Ph.D.  
TJ Whitaker, Ph.D.  
Wan Chan, Ph.D.

Research Disclaimer:

Author has an unrelated grant with Varian Medical Systems.

Spelling Disclaimer:



# Mining data to develop planning and treatment quality metrics



Most of the work

Planting Ideas, Cultivating a data focused culture  
Enabling technologies and clinical processes

Big Data

Metrics for Plan Quality



# QUANTEC: VISION PAPER

## THE LESSONS OF QUANTEC: RECOMMENDATIONS FOR REPORTING AND GATHERING DATA ON DOSE-VOLUME DEPENDENCIES OF TREATMENT OUTCOME

ANDREW JACKSON, PH.D.,\* LAWRENCE B. MARKS, M.D.,<sup>†</sup> SOREN M. BENTZEN, PH.D., D.Sc.,<sup>‡</sup>  
AVRAHAM EISBRUCH, M.D.,<sup>§</sup> ELLEN D. YORKE, PH.D.,\* RANDAL K. TEN HAKEN, PH.D.,<sup>§</sup>  
LOUIS S. CONSTINE, M.D.,<sup>||</sup> AND JOSEPH O. DEASY, PH.D.,<sup>¶</sup>

From the \*Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>†</sup>Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC; <sup>‡</sup>Department of Human Oncology, University of Wisconsin Medical School, Madison, WI; <sup>§</sup>Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; <sup>||</sup>Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY; and <sup>¶</sup>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO



# QUANTEC: VISION PAPER

## IMPROVING NORMAL TISSUE COMPLICATION PROBABILITY MODELS: THE NEED TO ADOPT A "DATA-POOLING" CULTURE

JOSEPH O. DEASY, PH.D.,\* SOREN M. BENTZEN, PH.D.,<sup>†</sup> ANDREW JACKSON, PH.D.,<sup>‡</sup>  
RANDALL K. TEN HAKEN, PH.D.,<sup>§</sup> ELLEN D. YORKE, PH.D.,<sup>||</sup> LOUIS S. CONSTINE, M.D.,<sup>‡</sup>  
ASHISH SHARMA, PH.D.,<sup>¶</sup> AND LAWRENCE B. MARKS, M.D.,\*\*

From the \*Department of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO; <sup>†</sup>Department of Human Oncology, University of Wisconsin School of Medicine, Madison, WI; <sup>‡</sup>Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>§</sup>Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; <sup>||</sup>Department of Radiation Oncology, University of Rochester Cancer Center, Rochester, NY; <sup>¶</sup>Center for Comprehensive Informatics, Emory University, Atlanta, GA; and \*\*Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC



# QUANTEC: ORGAN-SPECIFIC PAPER

## Central Nervous System: Optic Nerve/Chiasm

### RADIATION DOSE-VOLUME EFFECTS OF OPTIC NERVES AND CHIASM

CHARLES MAYO, PH.D.,\* MARY K. MARTEL, PH.D.,<sup>†</sup> LAWRENCE B. MARKS, M.D.,<sup>‡</sup>  
JOHN FLICKINGER, M.D.,<sup>§</sup> JIBO NAM, M.D.,<sup>‡</sup> AND JOHN KIRKPATRICK, M.D., PH.D.,<sup>¶</sup>

\*Department of Radiation Oncology, University of Massachusetts School of Medicine, Worcester, MA; <sup>†</sup>Department of Radiation Oncology, M. D. Anderson Cancer Center, Houston, TX; <sup>‡</sup>Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC; <sup>§</sup>Department of Radiation Oncology, University of Pittsburgh Presbyterian Hospital, Pittsburgh, PA; <sup>¶</sup>Department of Radiation Oncology, Duke University Medical Center, Durham, NC

### The Current Paradigm




Fig. 2. "The current (data-loss) paradigm." Data are effectively lost to the wider scientific community after publication. Capturing key datasets in query-able data repositories would accelerate the discovery of causative factors and increase the accuracy of parameter estimates.





Fig. 1. Why does normal tissue complication probability (NTCP) modeling frequently lead to incompatible results? The current paradigm consists of applying a range of evolving methods (models tested, structures included, etc.) to datasets that at least partially differ in patient, disease, and treatment characteristics. This inevitably leads to inconsistent results and impedes the validation of NTCP models for broad clinical use. It will be necessary to pool data to escape this trap.

We want to "follow the data" to make meaningful decisions on how to improve treatments to get better outcomes for our patients.


There is significant heterogeneity in treatment parameters that vary among clinics, providers, time, technology, etc. . To tease out details on what can be shown to matter, large , detailed, longitudinal datasets are needed.

It should be easier to show what treatment factors correlate with outcomes



# “The Coming Era of Big Data”

## What is pushing health care there ... Affordable Care Act



TITLE III—IMPROVING THE QUALITY AND EFFICIENCY OF HEALTH CARE	
Subtitle A—Transforming the Health Care Delivery System	
PART 1—LINKING PAYMENT TO QUALITY OUTCOMES UNDER THE MEDICARE PROGRAM	
Sec. 3001. Hospital Value-Based purchasing program .....	266
Sec. 3002. Improvements to the physician quality reporting system .....	277
Sec. 3003. Improvements to the physician feedback program .....	279
Sec. 3004. Quality reporting for long-term care hospitals, inpatient rehabilitation hospitals, and hospice programs .....	282
Sec. 3005. Quality reporting for PPS-exempt cancer hospitals .....	285
Sec. 3006. Plans for a Value-Based purchasing program for skilled nursing facilities and home health agencies .....	286
Sec. 3007. Value-based payment modifier under the physician fee schedule .....	288
Sec. 3008. Payment adjustment for conditions acquired in hospitals .....	291
PART 2—NATIONAL STRATEGY TO IMPROVE HEALTH CARE QUALITY	
Sec. 3011. National strategy .....	293
Sec. 3012. Interagency Working Group on Health Care Quality .....	295
Sec. 3013. Quality measure development .....	296
Sec. 3014. Quality measurement .....	300
Sec. 3015. Data collection; public reporting .....	304

**We need to define the metrics that are going to be used to define to quality measurement**

***Should be clinically useful, should be gettable from automated processes***

## Taussig Cancer Institute




Cleveland Clinic

2013  
Outcomes

## Fatigue Status at Discharge 2012 – 2013

## Palliative Medicine

Percent of Patients Reported




Status as reported by 584 patients with fatigue on admission/transfer or discharge in 2013; symptom assessed for 724 inpatients in 2013, including symptoms data for expired patients up to the time of death.

Our commitment to transparent reporting of accurate, timely information about patient care reflects Cleveland Clinic's culture of continuous improvement and may help referring physicians make informed decisions.

## Symptoms Present at Admission and Discharge 2013

## Palliative Medicine


Percent of Patients Reported



Symptoms assessed and reported for 1108 inpatients in 2013, including symptoms data for expired patients up to the time of death.

## Measuring Outcomes Promotes Quality Improvement

### Biochemical Relapse-Free Survival of Patients with Intermediate-Risk Prostate Cancer by Treatment Type (N = 3922) 1996 – 2013




Percent Biochemical Relapse-Free Survival and (Number at Risk)

Treatment Type	5-Year	10-Year
External beam radiotherapy	85 (259)	72 (101)
Low-dose-rate brachytherapy	91 (286)	81 (25)
Radical prostatectomy	83 (337)	73 (108)

P value from log-rank test. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemother Rep.* 1966;50(3):163–170.

Low-, intermediate-, and high-risk stratification done per National Comprehensive Cancer Network (NCCN) criteria. NCCN Clinical Practice Guidelines in Oncology – Prostate Cancer. Version 2.2007, Apr. 9, 2007. National Comprehensive Cancer Network, Inc.

### Biochemical Relapse-Free Survival of Patients with High-Risk Localized Prostate Cancer by Treatment Type (N = 3057) 1996 – 2013




Percent Biochemical Relapse-Free Survival and (Number at Risk)

Treatment Type	5-Year	10-Year
External beam radiotherapy	74 (366)	52 (103)
Low-dose-rate brachytherapy	75 (69)	47 (5)
Radical prostatectomy	60 (172)	47 (44)

### Five-Year Relative Survival of Patients with Breast Cancer by Stage at Diagnosis (N = 4154) 2006 – 2012

Percent Survival




- Periodic Cleveland Clinic report (~83 pages) provided to physicians to give detailed data on outcomes for **all** disease sites.
- Example of how routine collection of data can be incorporated into clinician discussions of evidence based medicine and used as a baseline to better inform patients.
- Requires a commitment to “follow the data”

# Knowledge Based Clinical Practice Improvement System (aka KPI or Kπ)

Mayo RadOnc System to routinely gather and analyze outcomes data for all patients

**Vision - Routine aggregation and analysis of data for all patients to inform practice on the effect of treatment choices on outcomes and direct improvements**



**The basis of knowledge is information**




## Data Dictionary of KPI Dev Data Elements as of 10/10/2014

**Enhanced Demographics:** Name, ClinicID, DOB, DOD(i.e. survival), County, State, Country, Postal Code, Race, Ethnicity, Religion, Marital Status, Gender, E-Mail

**Diagnosis and Staging:** Date of Entry, Basis, T,N,M + G,H,N,P,R,S, etc, OverallStage, StagingSystem, Laterality, ICD9 (ICD10), ICD0,Ranking, Primary Site, DistantMets, Recurrence, ICD9 of Primary,Diagnosis Date, Diagnosis Method

**Toxicity:** Date, Grading System, Grade, Cause, Certainty

**Patient Reported Outcomes:** Date of PRO, Templates, Questions , Answers 

**Labs(Current):** Height, Weight, BMI, Neutrophils, Platelet Count, Lymphocytes, Hemoglobin, Leukocytes, PSA (~ 3,000,000 rows of data  $\geq$  1/1/2011)

**Treatment Course:** CourseID, Course Start Date (based on treatment records), Course End Date (based on treatment records)

**Treatment Rx:** Number of course fractions, number of treatments per course fraction, dose to each target volume (i.e. all the data in the Rx in Planning Templates)

**Treatment Delivery Details for Each Plan:** Facility, Machine, NFractions Treated, NFractions Planned, Total Dose Delivered, Total Dose Planned, Number of Beams, Plan Name, Plan DicomUID, TotalMU, TotalBeamOnTime, TotalTreatmentDeliveryTime, TotalTreatmentSessionTime , IsProton, IsBrachy, IsSBRT, IsBreathHold, UsedStaticIMRT, UsedHybridIMRT, UsedVMATIMRT, UsedHybridVMAT, UsedWedges, UsedNonCoplanarBeams, UsedHalfBeamX, UsedHalfBeamY, UsedIGRT, UsedCBCT, UsedX06, UsedX06FFF, UsedX10, UsedX10FFF,UsedX18, UsedX18FFF, UsedE06, UsedE09, UsedE12, UsedE16,UsedE20,CouchVrt\_Mean, CouchVrt\_Stdev, CouchLng\_Mean, CouchLng\_Stdev, CouchLat\_Mean, CouchLat\_Stdev, CouchRotation\_Mean, CouchRotation\_Stdev, CouchPitch\_Mean, CouchPitch\_Stdev, CouchRoll\_Mean,CouchRoll\_Stdev, (Other Brachy and proton specific items to be added)


**Treatment DVH Curves:** Structure, Volume[cc], Max[Gy],Min[Gy], Mean[Gy], Median[Gy], Stdev[Gy], DVH curve (Percent Volume vs Absolute Dose as point pairs)

**Treatment DVH Metrics:** Values stored for course composite plans (e.g. 1<sup>st</sup> course + Boost), as in planning templates. This enables rapid identification of patient groups according to metrics that are most relevant to disease site groups, ( i.e. find all esophagus patients with lung\_total:V20Gy[%] > 20) The treatment DVH curves can be used to pull other values, but the searches based on DVH curves are slower than searches on DVH metrics.

**Treatment Details Specific to Disease Site:** e.g. Breast target details questionnaire, CU Androgen questionnaire, Head and Neck HPV status

**Recurrence Status:** HadLocalRelapse,Date of Local Relapse, HadRegionallyLymphNodeRecurrence, Date of Regional LymphNodeRecurrence, HadDistant Relapse, Date of Distant Relapse, Site of Distant Relapse, Cause of Death (Cancer-Local, Cancer- Regional, Cancer-Distant, Treatment, Other, Unknown)

# How will our clinic be able to gather “Big Data”?



- Demographics
- Diagnosis and Staging
- Survival/Recurrence
- Provider Reported Toxicity
- Patient Reported Outcomes
- Treatment Plan Details
- DVH Metrics
- DVH Curves
- Chemotherapy
- Surgery
- Labs
- Imaging
- Treatment Delivery Details
- Treatment Approach Details

- Technology is a much smaller step than culture changes needed for implementation: consensus (inter and intra institutional), process, changes in work duties, QA
- Can do a lot with existing treatment planning and radiation oncology information systems
- Think through what data elements you want /need in the long run, how they are related and then develop a strategy of small, manageable steps.

# How to get there ?

## Technology

- Software/database systems for aggregating information
- Software systems for analytics
- Integration with other systems

### A few options here

- DIY – Use in house staff with expertise or train
- Use consultants to help build
- Purchase from current vendor (ROIS,TPS)
- Purchase from 3<sup>rd</sup> party vendor

## Culture

- Need to shift thinking about data related to treating our patients.
- Thinking about the data not just for treatment of the patient before us , but for systematic aggregation to help all the patients yet to come.
- Implication is accepting limitations in options, standardizations
- Potentially more work to quantify data – “free text” is hard to use

### This... only you can do

*Assume you have the technology, what do you have to change about your practice to enable the technology to get the data?*

- Consensus in your practice
- Standardize practice
- Change who does what

## Baby Steps – a lot of them

To move a group you have to help them believe in the vision.  
As you create working examples that show it is real and doable, then they will lead the way.

Pick working examples that can positively impact work flow in clinic and add value to current practice

Identify and tackle the “enabling” steps one by one. This positions you to grow your effort.


# Standardization and nomenclatures are needed to enable the automation needed to handle Big Data

**“Mind? I have no mind.  
I’m a computer.”**

*A foolish consistency is the hobgoblin of little minds,  
adored by little statesmen and philosophers and divines.*

*Ralph Waldo Emerson-Self Reliance*

**and database programmers**



*Manual effort is the enemy, free text is its cousin*

*Cost, FTE, Inconsistency, Speed*

## Standardize Diagnosis and Staging

Assume you are going to use standard codes (ICD-9/10, ICD-0, TNM+, histology, etc) to filter your searches to find the patients of interest to you.

- What information is input for every patient?
- How do you handle metastatic sites?  
e.g. is metastatic prostate 198.5 with a secondary of 185?
- Is the diagnosis and staging linked to the course for easy, computer lookup?
- Are you inputting courses and diagnosis from outside institutions so that you have a complete record?
- Have you put in place a QA process/peer review to be sure you are not going to have doubts about the data when you look back?

### This... only you can do

*Assume you have the technology, what do you have to change about your practice to enable the technology to get the data?*

- Consensus in your practice
- Standardize practice
- Change who does what

# ARIA Diagnosis and Staging Section


Summary	Registration	Encounters	Care Path	<b>Diagnosis</b>	Cancer Management	Health	Evaluation	Documents	Communication	Journal																								
<table border="1"><thead><tr><th>Clinical Description</th><th>Code</th><th>Stage</th><th>Criteria</th><th>Status Date</th><th>Dx Date</th><th>Status</th><th>Type</th><th>Source</th><th>Historic</th><th>Reported</th><th>New</th></tr></thead><tbody><tr><td>Malignant neoplasm of upper-outer quadrant of female breast</td><td>174.4</td><td>Stage X</td><td>T2, pN1mi, M0, G3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>											Clinical Description	Code	Stage	Criteria	Status Date	Dx Date	Status	Type	Source	Historic	Reported	New	Malignant neoplasm of upper-outer quadrant of female breast	174.4	Stage X	T2, pN1mi, M0, G3								
Clinical Description	Code	Stage	Criteria	Status Date	Dx Date	Status	Type	Source	Historic	Reported	New																							
Malignant neoplasm of upper-outer quadrant of female breast	174.4	Stage X	T2, pN1mi, M0, G3																															
<div><b>RT Summary</b>   <b>MedOnc Summary</b></div> <div><b>Course &amp; Diagnosis</b></div> <div>planning</div> <div>1 Rt CW nodes</div> <div>174.4, Malignant neoplasm of upper-outer quadrant of female breast</div>																																		
<div><b>Definition</b>   Pathology   Lesions   Staging   Tumor Markers</div> <div><div>Dx Date: <input type="text" value="3/6/2015"/></div><div>Code: 174.4 <input type="button" value="Q"/></div><div>Code Type: ICD-9-CM <input type="button" value="Q"/></div><div>Code Desc: Malignant neoplasm of upper-outer quadrant of female breast</div><div>Clinical Desc: Malignant neoplasm of upper-outer quadrant of female breast</div><div>Details: Mastectomy with axillary lymph node dissection Adjuvant chemotherapy - AC x 4, taxol x 5 doses (discontinued due to peripheral neuropathy)</div><div>Status: Active <input type="button" value="Q"/></div><div>Ranking: Primary <input type="button" value="Q"/></div><div>Confirmed: <input type="checkbox"/> Final Coding <input type="checkbox"/> Dx Method: Histology/Pathology <input type="button" value="Q"/></div><div>Method Desc: <input type="button" value="Q"/></div></div> <div><div><input checked="" type="radio"/> Diagnosis <input type="radio"/> Problem</div><div>Dx Category: Breast <input type="button" value="Q"/></div><div>Dx Site: Breast <input type="button" value="Q"/></div><div>ICD-O Site: Upper-outer quadrant of breast - C50.4 <input type="button" value="Q"/></div><div>Cancer Behavior: Malignant, primary site <input type="button" value="Q"/></div><div>Laterality: Right side <input type="button" value="Q"/></div><div>Primary Dx: <input type="button" value="Q"/></div><div>Primary Site: Breast <input type="button" value="Q"/></div><div>Distant Mets: No <input type="button" value="Q"/></div><div>Recurrence: No <input type="button" value="Q"/></div></div>																																		

Definition **Pathology** | Lesions | Staging | Tumor Markers

Pathology Item	Details
Cell Histology	Category: Ductal; Type: Ductal carcinoma; Grade III - Poorly differentiated
Tumor Size Assessment	Measurement: Gross; Largest Focus: 3.1 cm; Multi-Focal: Yes
Margin Assessment	Status: Negative; Location: Surgical Margins: Negative for invasive carcinoma: nearest anterior superior margin, 0.2 cm. Negative for DCIS: nearest anterior superior margin, < 0.1 cm.
Invasive Tumor Details	Invasive Tumor: Yes; Lymphovascular invasion: Present (not otherwise specified)
DCIS	Present (not otherwise specified)
Necrosis (associated with DCIS)	
Micro-calcifications	Present (not otherwise specified)
Node Assessment	16 Examined; 1 Positive (> 0.2 mm); Largest Node: 0.015 cm; ECE: Present (not otherwise specified)
ER Status	Positive
PR Status	Positive
S-Phase(%)	
Ki-67	Ki-67 Status: Positive; Ki-67(%): 63.8%
HER2/neu Details	IHC: 0-1+/Not amplified
OncotypeDX Details	



Once you standardize diagnosis and staging, you are in position to query your existing ROIS database to get a wealth of information on your practice. The tech is relatively easy.





Patient ID	Used Static IMRT
Course ID	Used VMAT IMRT
Course Start Date	Used Hybrid IMRT
Course End Date	Used Hybrid VMAT
Treatment Facility	Used Wedges
Treatment Machine	Used Non-Coplanar Beams
Physician	Used Half Beam X
Plan ID	Used Half Beam Y
Plan Dicom UID	Couch Vrt Mean
Is Plan Sum	Couch Vrt Standard Deviation
Is Course Cumulative	Couch Lat Mean
N Fractions Planned	Couch Lat Standard Deviation
N Fractions Treated	Couch Lng Mean
Dose Per Fraction	Couch Lng Standard Deviation
Total Dose Planned	Couch Rotation Mean
Total Dose Delivered	Couch Rotation Standard Deviation
N Beams	Couch Pitch Mean
Primary Reference Point	Couch Pitch Standard Deviation
Total Plan MU	Couch Roll Mean
Is SBRT	Couch Roll Standard Deviation
Is Breath Hold	Couch Yaw Mean
Used X06	Couch Yaw Standard Deviation
Used X06 FFF	Diagnosis Ranking
Used X10	Diagnosis ICD9
Used X10 FFF	Overall Stage
Used X18	Staging Information
Used X18 FFF	Laterality
Used E06	Primary ICD9
Used E09	
Used E12	
Used E16	
Used E20	

**Once you standardize your inputs, you can pull large data sets from your existing ROIS system to answer many clinical questions**

- Find me all the patients treated for metastatic prostate cancer with SBRT at facility X in the last year.
- Find me all the breast patients treated with IMRT in the last 3 years for whom we used a couch kick.
- Find me all the left sided stage IA lung cancer patients for whom we used an 18MV beam.
- Calculate statistics on the range of couch variation for each of our treatment sites so that we can use it to set our couch tolerances.
- Calculate the last year's work load for machine X so that we can use it in the shielding calculation for our replacement machine.
- Find me all the breast patients we treated with breath hold.
- Find me all the SBRT liver plans that I treated last year using VMAT.

## How can big data fit into making our patient's more safe?




- Insert a statistical layer for consistency check of parameters with historical probability distributions for the parameters.
- Different doesn't mean wrong (not different doesn't mean right) but it does highlight attention for a closer look.




## Using information from treatment records to define “expected” probability distributions

Retrospective statistics could be used in an automated plan check program to highlight sections for special attention


### How many MU's is unusual?



## How should we set our tolerance tables base on our experience?



## Can we predict couch height by patient weight?



Build consensus with physician disease site groups define standard DVH metrics and objectives to use for all patient treatment plans ~ 18 months

- Supports physician lead initiative to develop and define standards of practice for treatment plans.
- Replace free text word documents with standardized tabular templates
- Critical point in dialog for building consensus is distinction between agreement on what metrics we measure vs. the the constraint value and priority

Agree on what to measure for all

lung\_total V20Gy[%] < 25% Priority = 1

Enable per patient change from default of constraint/priority

- While defining vanilla (standard), must take an approach that allows for chocolate (per patient changes)

Planning Fraction	Number of Fractions	Dose to PTV_High (Gy)	Dose to PTV_Intermediate (Gy)	Dose to PTV_Low (Gy)
Tx				
Boost 1				
Boost 2				
Total				

PTV_High contains	
PTV_Intermediate contains	
PTV_Low contains	

Bolus: None Additional Instructions:

A treatment plan should be constructed that covers targets with prescribed doses while reducing the magnitude and volume of hot (>108% x Rx Dose) spots. Doses to normal tissues and organs should be kept as low as reasonably achievable. In addition the following specific objectives or evaluation metrics are given.

Must: Plan must pass this constraint in order to be accepted

Consult: Stop planning process to consult with the physician if there are problems passing this constraint.

Desirable or Lower-Constraint: Try to achieve, but do not stop planning process to consult with physician if there are problems passing this constraint. Plan will pass if constraint cannot be met. If plan is not done by a senior dosimetrist or physicist experienced with this plan type, confirm with one of these that the constraint cannot be met. Specification of Lower-Constraint is used when there is more opportunity for sparing because disease at that level is ipsilateral

Structure	DVH Endpoint	Constraint Value	Planning Priority
ptv_high	D95%(%)	> 100%	Must
	Min_Dose(%)	> 95%	Consult
	Min_Dose(Gy)		Report
	Mean_Dose(Gy)		Report
	Max_Dose(Gy)		Report
	Max_Dose(%)	< 115%	Must
	D1%(%)	< 110%	Consult
ptv_intermediate	D95%(%)	> 100%	Must
	Min_Dose(Gy)		Report
	Mean_Dose(Gy)		Report
	Max_Dose(Gy)		Report
ptv_low	D95%(%)	> 100%	Consult
	Min_Dose(Gy)		Report
	Mean_Dose(Gy)		Report
	Max_Dose(Gy)		Report
ctv_high	V100%(%)	> 98%	Consult
	Min_Dose(Gy)		Report
	Mean_Dose(Gy)		Report
	Max_Dose(Gy)		Report
ctv_intermediate	V100%(%)	> 99%	Must
	Min_Dose(Gy)		Report

# Standardize structure and DVH Nomenclatures along with Rx and DVH metrics measured

Normal tissue naming schema is left to right: general to specific with laterality at the end.  
 Character string length, use of capitals, spaces, etc are guided by vended systems used in the clinic  
 (simulator, planning system, information system, etc) constrain format

For targets (PTV, CTV, GTV, ITV)  
 take an approach  
 that allows a standard  
 name plus an alias in  
 the database  
 e.g. ptv\_high = PTV7200

Using both a standard name  
 and an alias, means when  
 pulling data from the database  
 we can identify the volume  
 getting the highest dose  
 for any plan or treatment  
 site (ptv\_high) independent  
 of the specific name used in  
 the plan (ptv6300).

Partial list of our structure nomenclature						
Mayo Clinic Radiation Oncology		Standard Structure Nomenclature		version- 20130328		
ptv_high		semi_cir_canal_l		parotid_total		
ctv_high		semi_cir_canal_r		parotid-ptv_r		
itv_high		ext_aud_canal_l		parotid-ptv_l		
gtv_high		ext_aud_canal_r		parotid-ptv_total		
ptv_intermediate		mastoid_l		sub_mandib_r		


TemplateName	PlanName	Structure	DVHMetric	DVHMetric_Value	Alias_PTV_High	Alias_PTV_Low
Breast - Simple	R breast	ptv_high	D5[%]	85.8196	ptv5256	ptv4256
Breast - Simple	R breast	ptv_high	Min[%]	76.75799	ptv5256	ptv4256
Breast - Simple	R breast	ptv_high	V110[%cc]	0	ptv5256	ptv4256
Breast - Simple	R breast	ptv_high	V115[%cc]	0	ptv5256	ptv4256
Breast - Simple	R breast	ptv_low	CV90[%]	0.6428106	ptv5256	ptv4256
Breast - Simple	R breast	ptv_low	Mean[Gy]	43.728	ptv5256	ptv4256
Breast - Simple	R breast	ptv_low	Min[%]	31.97838	ptv5256	ptv4256

ptv_low		optic_nrv_r		oral_cavity		
TemplateName	PlanName	Structure	DVHMetric	DVHMetric_Value	Alias_PTV_High	Alias_PTV_Low
Prostate - ConvFX	Pelvic region	ptv_high	Max[%]	108.2555	ptv6300	ptv5400
Prostate - ConvFX	Pelvic region	ptv_high	Mean[Gy]	64.72	ptv6300	ptv5400
Prostate - ConvFX	Pelvic region	ptv_high	V99[%]	97.16188	ptv6300	ptv5400
Prostate - ConvFX	Pelvic region	ptv_high	V100[%]	94.32925	ptv6300	ptv5400
Prostate - ConvFX	Pelvic region	ptv_high	V107[%]	0.04317822	ptv6300	ptv5400
Prostate - ConvFX	Pelvic region	ptv_high	Volume[cc]	56.4	ptv6300	ptv5400
Prostate - ConvFX	Pelvic region	ptv_low	CV98[%]	3.741312	ptv6300	ptv5400
Prostate - ConvFX	Pelvic region	ptv_low	D98[%]	90.59662	ptv6300	ptv5400
Prostate - ConvFX	Pelvic region	ptv_low	Mean[Gy]	57.481	ptv6300	ptv5400
Prostate - ConvFX	Pelvic region	ptv_low	V98[%]	96.25869	ptv6300	ptv5400
Prostate - ConvFX	Pelvic region	ptv_low	V99[%]	95.51831	ptv6300	ptv5400

brain		eye_r		constrictors_p		
brain-ptv		eye_l		constrictors_p-ptv		

Define a DVH nomenclature schema that fully defines all parts of the curve and can be expanded upon to accommodate other DVH derived metrics as they evolve.

*endpoint name(calculation parameters)[output units]*



Example of use for radiobiological metrics: V35EQ2Gy(4)[%]

# Several groups are coordinating efforts to address nomenclature for radiation oncology

## NRG Oncology

### BRIEF REPORT AND OPINION

## Radiation Therapy Digital Data Submission Process for National Clinical Trials Network

Jialu Yu, PhD,\* William Straube, MS,<sup>†</sup> Charles Mayo, PhD,<sup>‡</sup>  
Tawfik Giaddui, PhD,\* Walter Bosch, DSc,<sup>†</sup> Kenneth Ulin, PhD,<sup>§</sup>  
Stephen F. Kry, PhD,<sup>||</sup> James Galvin, DSc,\* and Ying Xiao, PhD\*

\*IROC/NRG/Jefferson Medical College, Philadelphia, Pennsylvania; <sup>†</sup>IROC St. Louis, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; <sup>‡</sup>Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; <sup>§</sup>IROC Rhode Island, University of Massachusetts Medical School, Lincoln, Rhode Island; and <sup>||</sup>IROC Houston, Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas

Received May 6, 2014, and in revised form May 28, 2014. Accepted for publication May 30, 2014.

International Journal of  
Radiation Oncology  
biology • physics

www.redjournal.org



BrainStem_“exp”	“exp” can be a two digit number representing the uniform expansion of the Brain stem for a specific planning risk volume (PRV) margin in mm.
BrainStem_PRV	Brains Stem expanded with a non specific planning risk volume
BrainStemCore	core of the brains stem
BrainStemSurf	Surface of the brain stem
Breast_L	Left Breast
Breast_R	Right Breast
CaudaEquina	CaudaEquina
ChestWall	Chest Wall
Cochlea_L	Left Cochlea
Cochlea_R	Right Cochlea
Colon	Colon
CommonBileDuct	Common Bile Duct
Duodenum	Duodenum
Ear_External_L	External left Ear
Ear_External_R	External Right Ear
Ear_Middle_L	Left middle ear
Ear_Middle_R	Right middle ear
Esophagus	Esophagus
Esophagus_Lo	lower esophagus
Esophagus_Up	upper (cervical) esophagus
External	External patient contour encompassing all patient anatomy with a single contour on each slice
Eye_L	Left eye
Eye_R	right eye
Femur_L	Left Femur
Femur_R	Right Femur
Femurs	Both Femurs
GallBladder	Gall Bladder
GreatVessels	Great Vessels
Heart	Heart
Hippocampus_L	left Hippocampus
Hippocampus_R	right hippocampus
Hypothalamus	hypothalamus
IVC	Inferior Vena Cava
Jejunum_Ileum	Jejunum/Ileum
Kidney_L	Left Kidney
Kidney_R	Right Kidney
Kidneys	Both Kidneys

## AAPM Task Group No. 263 - Standardizing Nomenclature for Radiation Therapy

Members represent multiplicity of stake holders – institutions, vendors, national regions and international, academic/non-academic, physicians, physics, AAPM/ASTRO
































**Left Optic Nerve(12):** Lt Optic Nerve, OPTICN\_L, OPTNRV\_L, optic\_nrv\_l, L\_optic\_nerve, OPTIC\_NRV\_L, OpticNerve\_L, LOPTIC, OpticNerve\_L(3), Lef Optic Nerve

**Left Lung(12):** Lt Lung, Lung\_L(4), LUNG\_L(3), lung\_l, L\_lung, LLUNG, LLung

**Both Lungs(12):** Lungs(2), LUNGs, LUNG\_TOTAL, lung\_total, combined\_lung, LUNG, LUNGs(2), Lung, BilatLung, Lung\_Both

**8th cranial nerve(7):** CN\_VIII(5), cn\_viii(2)


**Right External Iliac Artery(2):** A\_ILLIAC\_E\_R, a\_iliac\_e\_r

 Tara Archambault, MSc 6/30/2014-12/31/2016 Member - (pending)	 Walter S. Bosch, DSc 6/30/2014-12/31/2016 Member - (pending)	 Mary E. Nagel, PhD 6/30/2014-12/31/2016 Member - (pending)	 Richard A. Phipps, PhD 6/30/2014-12/31/2016 Consultant - (pending)
 Stephen L. Brown, PhD 6/30/2014-12/31/2016 Consultant - (pending)	 Antonella Fagiano-Cost, PhD 6/30/2014-12/31/2017 Consultant - (pending)	 Thomas G. Purdie, PhD 7/26/2014-12/31/2017 Consultant - (pending)	 Susan L. Richardson, PhD 6/30/2014-12/31/2016 Consultant - (pending)
 Peter Gabriel, MD 10/30/2014-12/31/2017 Member - (pending)	 Weigang Hu 10/30/2014-12/31/2016 Consultant - (pending)	 Russell L. Rao 6/30/2014-12/31/2016 Member - (pending)	 Lakshmi Sankaran, PhD 6/30/2014-12/31/2016 Member - (pending)
 Cory Matthews, PhD 6/30/2014-12/31/2016 Member - (pending)	 Beth Sargent 6/30/2014-12/31/2017 Member - (pending)	 Salem Siddiqui, MD 6/30/2014-12/31/2016 Consultant - (pending)	 Benson Albrecht C. Smith, PhD 6/30/2014-12/31/2016 Member - (pending)
 Laurence D. Marks, MD 6/30/2014-12/31/2016 Member - (pending)	 Mary K. Martel, PhD 6/30/2014-12/31/2016 Consultant - (pending)	 Wilco Verbeek, PhD 6/30/2014-12/31/2016 Consultant - (pending)	 Qinghong Jackie Wu, PhD 6/30/2014-12/31/2016 Consultant - (pending)
 Martha M. Maassab, PhD 6/30/2014-12/31/2016 Member - (pending)	 Charles C. Mayo, PhD 6/30/2014-12/31/2016 Task Group Chair - (pending)	 Ying Xiao, PhD 6/30/2014-12/31/2016 Member - (pending)	 System Task 6/30/2014-12/31/2017 Member - (pending)
 Jodi K. McNair, PhD 6/30/2014-12/31/2016 Member - (pending)	 Jeff Michalski, MD 6/30/2014-12/31/2016 Member - (pending)	 Ellen D. Yorke, PhD 6/30/2014-12/31/2016 Consultant - (pending)	
 Robert Cliff Miller, MD 6/30/2014-12/31/2016 Member - (pending)	 Andrew Wolman, MS 6/30/2014-12/31/2016 Member - (pending)		
 Jean M. Moran, PhD 6/30/2014-12/31/2016 Member - (pending)	 Tomaz Morgan 10/30/2014-12/31/2016 Member - (pending)		



# What do you do when your nomenclature differs from the nomenclature for a TRIAD submission of DICOM files?

Write a script using Evil Dicom (thanks Rex Cardan, UAB).





Home / Browse / Science & Engineering / Medical Physics / Evil Dicom (classic)



**Evil Dicom (classic)**

Brought to you by: [rexcardan](#)



# Iterative Process

Building consensus on the IT design and function.

## Free text Word

Physician driven

## Standardized formatted Word

Physician + Physicist driven

Stand alone application that demonstrates automation and software driven templates

Physicist + Physician driven

Production application that uses database

IT driven with multidisciplinary committee: physicians, dosimetrists, therapists, physicists

Planning Fraction	Number of Fractions	Dose to PTV_High (Gy)	Dose to PTV_Intermediate (Gy)	Dose to PTV_Low (Gy)
TV				
Boost 1				
Boost 2				
Total				

+

PTV\_High contains  
PTV\_Intermediate contains  
PTV\_Low contains

Bolus: None

Additional Instructions

A treatment plan should be constructed that covers targets with prescribed doses while reducing the magnitude and volume of hot (>100% x Rx Dose) spots. Doses to normal tissues and organs should be kept as low as reasonably achievable. In addition, the following specific objectives or evaluation metrics are given.

Must: Plan must pass this constraint in order to be accepted.

Consult: Stop planning process to consult with the physician if there are problems passing this constraint.

Desirable or Lesser Constraints: Try to achieve, but do not stop planning process to consult with physician. If there are problems passing this constraint, Plan will pass if constraint cannot be met. If plan is not done by a senior dosimetrist or physicist experienced with this plan type, confirm with one of them that the constraint cannot be met. Specification of Lower-Constraints is used when there is more opportunity for sparing because doses at that level is important.

Structure	DVH Endpoint	Constraint Value	Planning Priority
ptv_high	D95%[%]	> 100%	Must
	Min_Dose [%]	> 95%	Consult
	Min_Dose [Gy]		Report
	Mean_Dose [Gy]		Report
	Max_Dose [Gy]		Report
	Max_Dose [%]	< 115%	Must
	D1%[%]		Consult

1. Mayo Clinic Treatment Planning Template

Print Save Open Write to XML

Constraints Selection

Prescription Constraints: Head and Neck Normal Tissue Constraints: Head and Neck-QD

Patient Information

Last Name: First Name: MICK

Target Dose Volume Definitions

Number of target dose levels in this plan: 3

Relative Dose Level Alias Contains

ptvhigh

ptvintermediate

ptvlow

Prescription Fractions

Number Fractionation: 1

Fractionation Group Number of Fractions ptvhigh ptvintermediate ptvlow

1st course

Total 0 0 0 0

Bolus: No Additional Instruction

Prescription DVH Constraints

ptv\_high

D95%[%] >= 100 % Must

Min[%] Report

CV95%[cc] < 0.5 Consult

Max[%] Report

V115%[cc] < 0.5 cc Must

ptv\_intermediate

ptv\_low

1. KCS RT - Editing Planning Template for Testing: Ann 03-303-925

View How-To Guide...

Clinic Number: 03-303-925 Birth Date: 23-Jun-1982

Patient Name: Testing, Ann Gender: F Physician: chone Selected

Plan Name: Std HN Scan Location: Edges Plan Type: 3D Choral Setup: SBRT Details

Protocol #: Plan in: Edges SIM Plans: IMRT Details

Technique: Per Plan Modality: Per Plan Dose Spec: Per Plan

Prescription Constraints: Head and Neck Normal Tissue Constraints: Head and Neck

Prescription DVH Constraints Add

Structure	DVH Endpoint	Constraint Value	Planning Priority
ptv_high	Max[Sv]	Report	
	Max[%]	Report	
	Min[%]	Report	
	Max[%]	Report	
	Mean[Sv]	Report	
	D12[%]	<= 110 % 2	
	D95[%]	>= 100 % 1	
	V115[cc]	< 0.5 cc 1	
	CV95[cc]	< 0.5 cc 2	
ptv_low	Max[Sv]	The volume receiving 95 % of the prescribed dose or less, Volume expressed in cc.	
	Max[Sv]	Report	
chv_high	D95[%]	>= 100 % 2	
	Max[Sv]	Report	
	Max[%]	Report	
chv_low	Max[Sv]	>= 98 %	Report
	Max[Sv]	Report	
	V100[%]	>= 99 % 2	

Normal Tissue DVH Constraints Add

Save Cancel

Application becomes our standard prescription.

Also serves as documentation tool for image setup, notes, IMRT justification, etc.

Physician groups define consensus for DVH metrics for all treatment sites; what to measure and default values for constraints and prioritizations.

ICIS RT - Editing Planning Template for Testing, Ann 03-303-925

Clinic Number: **03-303-925** Birth Date: **23-Jun-1982** [View How-To Guide...](#)  
Patient Name: **Testing, Ann** Age: **31**  
Gender: **F** Physician: **<None Selected>**

Plan Name: **Std HN** Scan Location: **Eclipse** Plan Type: ☐ 3D ☐ Clinical Setup ☐ SBRT [Details...](#)  
Protocol #:  Plan in: **Eclipse** ☒ SIM Films ☐ IMRT [Details...](#) ☐ IGRT [Details...](#)  
Technique: **Per Plan** Modality: **Per Plan** Dose Spec: **Per Plan**

Prescription Constraints: **Head and Neck**  
Prescription DVH Constraints:  
☒ ptv\_high  
☒ ptv\_low  
☒ ctv\_high  
☒ ctv\_low

Normal Tissue DVH Constraints:  
2 Dose Level  
1 Dose Level  
X - No DVH Constraints

Normal Tissue Constraints: **Head and Neck**

Constraint Value	Plan
110 %	2
100 %	1
0.5 cc	1
0.5 cc	2
95 % of the prescribed dose	
100 %	2
98 %	2
99 %	2

Save Cancel



Now generate a report as part of routine care that compares desired vs achieved DVH metrics for each patient . Use this in plan check to highlight areas for special attenuation.

## Save DVH metrics in database to mine results later

### Mayo Clinic Prescription and Dose/Volume Histogram

Clinic Number: Patient:   Gender:   DOB:  

Physician Signature:

RTP Name: 1 Prostate

Plan In: Eclipse

Technique: Per Plan

### Target Volume Definition

ptv7200 (ptv\_high)

ptv6480 (ptv\_low)

### Prescription

Nun

Initial Volume	36
----------------	----

Total	36
-------	----

**Bolus:** No

**Instructions:**



### Target DVH Objectives

ctv7200

- We constructed this system at a time when the vended system was very limited. Now more built in and scripting.
- Vended systems (ROIS/TPS) are maturing rapidly to enable standardization of nomenclature, prescriptions and reporting
  - Built in modules
  - Scripting capabilities
- You likely can use existing tools in your system to aggregate DVH metrics or use scripting APIs to create them.
- The most important step is to standardize on what to measure
- Then you are in position to begin learning from the statistics on your own experience

ptv7200

## Using the data to improve our practice – gains for research and quality improvement



Sets the stage for constructing plan check software that uses recent retrospective data on distributions of values for DVH metrics , for highlighting values for a new plan that should get extra attention.

Look beyond our just our own experience and put the results in the context of other institutions.



The poster is a dark blue rectangle with white text. On the left is the Mayo Clinic logo. On the right is the MD Anderson Cancer Center logo, which includes the text 'THE UNIVERSITY OF TEXAS' above 'MDAnderson Cancer Center'. A red horizontal line is drawn across the 'Cancer Center' text. The main title is centered in large white font. Below the title, the authors' names are listed. At the bottom left, there is small text about the poster number and date.

**MAYO CLINIC**

**What is normal?**

**Cooperative Pooled Database to Establish Typical Heart and Lung Doses for Modern Radiation Therapy**

IA Petersen\*, CS Mayo\*, SF Shaitelman#, MK Martel#, SS Park\*, WA Woodward#, RW Mutter\*, RM Howell#

\* Mayo Clinic, Department of Radiation Oncology, #MD Anderson Cancer Center, Department of Radiation Oncology

Poster 2116  
Monday, September 15, 2015  
5:30 - 6:45


THE UNIVERSITY OF TEXAS  
**MDAnderson**  
~~Cancer Center~~

Pool data among institutions to define what is normal


Explore variations in treatment techniques and effects on DVH parameters

Together these efforts position us to evaluate individual plans in the context of the history of previous plans


**Ipsilateral Lung V5Gy[%]**




**Ipsilateral Lung V13Gy[%]**



**Ipsilateral Lung V20Gy[%]**




**Ipsilateral Lung Mean[Gy]**




Median, box 50% CI, whiskers 95% CI


Heart Max[Gy]




Heart V25Gy[%]



Heart V4Gy[%]





Heart Mean[Gy]



Median, box 50% CI, whiskers 95% CI

Considering the pooled data prompted, ideas about how to improve.

Systematically gathering the data enabled demonstrating the improvement.



## Completing the loop




Use data on what was achieved in DVH metrics as basis to set new constraints to use as defaults for future plans in the planning templates.

Suggested Mean Doses (range)	Mean heart dose (Gy)	Ipsilateral lung V20(%)	Total Lung V20 (%)
<b>Tangential chest wall/breast</b>			
Right	4 → 0.5 (0.2 – 1.6)	15 → 10.4 (2.7 – 18.6)	10 → 5.8 (1.6 – 11.1)
Left	4 → 1.1 (0.3 – 5.1)	15 → 8.9 (0 – 19.2)	10 → 4.4 (0.2 – 9.4)
<b>Chest wall/breast + SCV</b>			
Right	4 → 1.9 (0.5 – 8.0)	25 → 24.0 (14.3 – 36.3)	10 → 15.0 (7.9 – 28.3)
Left	4 → 3.2 (0.7 – 9.1)	25 → 23.9 (9.9 – 36.7)	10 → 10.9 (4.7 – 15.9)
<b>Chest wall/breast + SCV + IM</b>			
Right	4 → 2.1 (0.5 – 5.4)	25 → 32.1 (9.8 – 44.2)	10 → 18.2 (5.7 – 29.3)
Left	4 → 4.0 (1.4 – 9.2)	25 → 27.7 (8.9 – 43.4)	10 → 13.1 (7.7 – 20.2)

## Conventional Lung Treatment DVH Metrics over 16 month period

Benchmark objective (red), overall median (dark dashed line) and 50%CI (light dashed line) are compared to moving 6 month window box and whisker plots (median, 50%CI, 90%CI) spaced at 3 month intervals.





*With routine collection of DVH metrics comes functionality for data pooling and one element for meaningful plan quality metrics that inform practice and address Affordable Care Act.*





# Using benchmarks to compare different practices

## Example Rectum:V65Gy[%] for 4 groups



# What about correlations of DVH metrics to toxicities?

Summary | Registration | Encounters | Care Path | Diagnosis | Cancer Management | Health **Evaluation** | Documents | Communication | Journal

Assessments

Review of Systems | Physical Exam | **Toxicities** | Performance Status | Questionnaires | Tests | Vital Signs | Chief Complaint / HPI | Impression / Plan | Quality Measures | Clinical Notifications


Date/Time	Status	Type	Toxicity	Sub-Component	Grade	Description
12/8/2014 3:34 PM	Entered	Blood/Lymphatic	Febrile neutropenia		0	None
2/12/2015 3:40 PM	Entered	Blood/Lymphatic	Lymph node pain		0	None
		Cardiac	Myocardial infarction		0	None
		Ear/labyrinth	Ear pain		2	Moderate pain; limiting instrumental ADL

**Toxicities**

Group: (Graded) Grading Criteria: NCI CTCAE V4.03 Date: 2/12/2015 Time: 3:40 PM


Type	Component	Sub-Component	Grade 0	Grade 1	Grade 2	Grade 3	Grade 4	Cause	Certain
Blood/Lymphatic	Febrile neutropenia		None	-	-	Present	Life-threatening consequence...		
Blood/Lymphatic	Lymph node pain		None	Mild pain	Moderate pain; limiting instrumental...	Severe pain; limiting self care ADL	-		
Cardiac	Myocardial infarction		None	-	Asymptomatic and cardiac enzymes mini...	Severe symptoms; cardiac enzy...	Life-threatening consequence...		
Ear/labyrinth	Ear pain		None	Mild pain	Moderate pain; limiting instrumental...	Severe pain; limiting self care ADL	-		
Eye	Dry eye		None	Asymptomatic; clinical or diagnostic o...	Symptomatic; multiple agents indic...	Decrease in visual acuity (<20/40); limi...	-		
Eye	Eye pain		None	Mild pain	Moderate pain; limiting instrumental...	Severe pain; limiting self care ADL	-		
Gastrointestinal	Dry mouth		None	Symptomatic (e.g., dry or thick saliva) ...	Moderate symptoms; oral intake alterat...	Inability to adequately aliment oral...	-		
Gastrointestinal	Dysphagia		None	Symptomatic; able to eat regular diet	Symptomatic and altered eating/swall...	Severely altered eating/swall...	Life-threatening consequence...		
Gastrointestinal	Mucositis oral		None	Asymptomatic or mild	Moderate pain; not	Severe pain; interferen...	Life-threatening consequence...		

Show Errors New Amend Copy Recent Graph... Approve OK Cancel



Remember to get the connection to diagnosis and staging right

Diarrhea : Black: Grade 0, Red: Grade 1



When is no data, data and when is it just no data?

Another iteration on changing culture to think about treatment records as like a scientist as well as like a clinician.

Summary | Registration | Encounters | Care Path | Diagnosis | Cancer Management | Health | **Evaluation** | Documents | Communication | Journal

Assessments

Review of Systems | Physical Exam | **Toxicities** | Performance Status | Questionnaires | Tests | Vital Signs | Chief Complaint / HPI | Impression / Plan | Quality Measures | Clinical Notifications

Date/Time	Status	Type	Toxicity	Sub-Component	Grade	Description
12/8/2014 3:34 PM	Entered	Blood/Lymphatic	Febrile neutropenia		0	None
12/8/2014 3:34 PM	Entered	Blood/Lymphatic	Lymph node pain		0	None
		Cardiac	Myocardial infarction		0	None
		Ear/labyrinth	Ear pain		2	Moderate pain; limiting instrumental ADL


**Toxicities**

Group: [Graded] Grading Criteria: NCI CTCAE V4.03 Date: 2/12/2015 Time: 3:40 PM


Type	Component	Sub-Component	Grade 0	Grade 1	Grade 2	Grade 3	Grade 4	Cause	Cause
Blood/Lymphatic	Febrile neutropenia		None	-	-	Present	Life-threatening consequence...		
Blood/Lymphatic	Lymph node pain		None	Mild pain	Moderate pain; limiting instrumental...	Severe pain; limiting self care ADL	-		
Cardiac	Myocardial infarction		None	-	Asymptomatic and cardiac enzymes mini...	Severe symptoms; cardiac enzy...	Life-threatening consequence...		
Ear/labyrinth	Ear pain		None	Mild pain	Moderate pain; limiting instrumental...	Severe pain; limiting self care ADL	-		Treatme Definite
Eye	Dry eye		None	Asymptomatic; clinical or diagnostic o...	Symptomatic; multiple agents indic...	Decrease in visual acuity (<20/40); limi...	-		
Eye	Eye pain		None	Mild pain	Moderate pain; limiting instrumental...	Severe pain; limiting self care ADL	-		
Gastrointestinal	Dry mouth		None	Symptomatic (e.g., dry or thick saliva) ...	Moderate symptoms; oral intake alterat...	Inability to adequately aliment oral...	-		Treatme Definite
Gastrointestinal	Dysphagia		None	Symptomatic; able to eat regular diet	Symptomatic and altered eating/swall...	Severely altered eating/swall...	Life-threatening consequence...		
Gastrointestinal	Mucositis oral		None	Asymptomatic or mild	Moderate pain; not	Severe pain; interferen...	Life-threatening consequence...		Treatme

Show Errors New Amend Copy Recent Graph... Approve OK Cancel


Diarrhea : Black: Grade 0, Red: Grade 1



Urinary Frequency: Black-Grade 0, Purple- Grade 1, Red-Grade 2



Urinary Frequency: Black-Grade 0, Purple- Grade 1, Red-Grade 2





# Summary



## Standardize

- Make the input data consistent so that computer systems can automatically extract and reliably process it.
- Build in QA processes on your data so that you will believe it

## Extract

- Use the capabilities of your current electronic systems
- The exercise of pulling large data sets from your existing ROIS and TPS systems will improve your understanding of connections and needed consistencies

## Extend

- Train or get outside help if you need it
- Coordinate with other groups interested in data pooling to strengthen your processes and put the data to use
- This will work best if efforts are coordinated among institutions

## Demonstrate

- Show use of data from your electronic systems to define your practice norms and demonstrate improvement
- Be prepared to iterate. Changing processes and changing minds takes sustained effort

*Changing culture to think as a scientist as well as a clinician about data usage will require more effort than constructing the technology to use it.*





